Breathlessness, night sweats, and weight loss on natalizumab

The Lancet

Volumn 380, Issue 9843, 2012, Pages 726-727

  Dahdaleh, D ^a   Altmann, D M ^b   Malik, O ^a   Nicholas, R S ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETA INTERFERON; C REACTIVE PROTEIN; NATALIZUMAB; TUBERCULOSTATIC AGENT;

ACID FAST BACTERIUM; ADULT; ANTIBIOTIC SENSITIVITY; ATELECTASIS; BACTERIUM IDENTIFICATION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE DURATION; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FEVER; HEMOPTYSIS; HUMAN; IRELAND; LETTER; LEUKOCYTE COUNT; LUNG LOBE; LUNG TUBERCULOSIS; MICROSCOPY; MONOCYTE; MULTIPLE SCLEROSIS; NEUTROPHIL COUNT; NIGHT SWEAT; PLEURA BIOPSY; PLEURA EFFUSION; PLEURISY; PRIORITY JOURNAL; SMOKING; SPUTUM ANALYSIS; THORAX PAIN; THORAX RADIOGRAPHY; THROMBOCYTE COUNT; TRAVEL; TREATMENT DURATION; TURKEY (REPUBLIC); WEIGHT REDUCTION;

EID: 84865382895     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61401-9     Document Type: Letter

References (5)

1. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov 2005; 4: 510-18. (Pubitemid 40861993)
2. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354: 924-33.
3. US Food and Drug Administration. Information on natalizumab (marketed as Tysabri). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/ucm107198.htm (accessed March 15, 2012).
4. Feng CG, Britton WJ, Palendira U, et al. Up-regulation of VCAM-1 and differential expansion of β integrin-expressing T lymphocytes are associated with immunity to pulmonary Mycobacterium tuberculosis infection. J Immunol 2000; 164: 4853-60. (Pubitemid 30238089)
5. Xu B, Wagner N, Pham LN, et al. Lymphocyte homing to bronchus-associated lymphoid tissue (BALT) is mediated by L-selectin/PNAd, alpha4beta1 integrin/VCAM-1, and LFA-1 adhesion pathways. J Exp Med 2003; 197: 1255-67. (Pubitemid 36617772)